Latest news with #probiotics
Vogue
11 hours ago
- Health
- Vogue
Can Probiotics Help With Mental Health?
The phrase 'gut feeling' may be truer than we originally thought. In recent years, numerous scientific studies have shown the close link between gut health and mental health—and it looks like probiotics may play an important role. 'The gut and mood are connected via the so-called gut-brain axis,' says Dr. Miriam Stengel of SRH Klinikum Sigmaringen in Germany. 'It was first described in the 19th century by Dr. Beaumont, who investigated how anger affects the production of stomach acid and stomach function,' she explains. According to research, understanding how the gut-brain axis works 'has led to the development of novel therapeutic approaches aimed at targeting the gut microbiota to improve brain disorders symptoms.' This research has led to the exploration of all sorts of microbiome-based therapeutic interventions—including the use of probiotics, prebiotics, and dietary interventions—as potential strategies aimed to support mental wellbeing. Emotions and the microbiome Since the 1980s, research has increasingly focused on the neurotransmitters, or chemical messengers, that exist in both the brain and in the gastrointestinal tract. These messengers influence many bodily functions—including emotional processes. But these messengers need a healthy microbiome. After all, the microbiome does a lot: It influences the immune system and helps to defend against pathogens; it produces anti-inflammatory substances and vitamins; it synthesizes or influences the production of neurotransmitters like serotonin, dopamine, and GABA. Probiotics and the gut 'In the last ten years, another 'organ' has been discovered—the gut microbiome, i.e. all living organisms including bacteria, viruses, and fungi that populate our large intestine and contribute to our bodily functions in a variety of ways,' says Stengel. Probiotics can specifically support this microbiome by supplementing beneficial bacterial cultures or promoting their growth. In this way, they could also indirectly influence emotional processes such as mood, stress processing, and motivation. What are psychobiotics? A healthy gut is an essential component of a healthy body, an insight that dates all the way back to Hippocrates who said that 'all diseases begin in the gut' over 2,000 years ago. Today, modern science is proving his point. In the discussion about emotional balance, the term 'psychobiotics'—special probiotic bacterial strains that influence the mood—is gaining traction.
Washington Post
2 days ago
- Health
- Washington Post
Improve your gut health with our new Try This: Gut Check newsletter
The Washington Post's 'Try This' podcast has a new companion — the Try This: Gut Check newsletter. It's a five-part newsletter series that breaks down what science actually says about how to support gut health without stress, supplements or confusing trends. I'm Cristina Quinn, and I'll be exploring questions like: What's the deal with probiotics? Do fermented foods really help? How do you actually eat more fiber without overhauling your life? Can I throw quinoa on everything?!
Times
3 days ago
- Health
- Times
The experts' guide to the probiotics that work
P robiotics, the 'gut-friendly' supplements and functional foods that purportedly transform your health, immunity and mental wellbeing, are part of a market worth £178 million — and rising. By 2035 it is estimated we will be spending £242 million on tending to our microbiome, the vast ecosystem of bacteria, fungi and yeasts that inhabit our intestines. But what happens when these products are subjected to scientific scrutiny of the highest order — do they really live up to their claims? Until now consumers had no way of telling if the probiotic pill they were popping was worth taking or better left on the shelf. 'The probiotic market has exploded, but choosing the right product remains incredibly challenging,' says Dr Gemma Walton, a researcher at the University of Reading's department of food and nutritional sciences. 'Well-researched products sit on the shelves next to others that may have very little research behind them.'
News.com.au
3 days ago
- Health
- News.com.au
Dr Boreham's Crucible: Microba Life Sciences
When Russian author Aleksandr Solzhenitsyn said the battle between good and evil runs through every man - ok, person - he was not talking about the trillions of bacteria that reside in the gut. But he may well have been, because this thriving ecosystem of bugs can make us very ill - or promote healthy functions such as digestion and immunity. In the main, they do the good stuff. Microba's reason for being is to help chronically unwell people by addressing their microbiome, which CEO Dr Luke Reid dubs the critical 'missing organ'. Gut health and the microbiome have been a trendy 'wellness' area, exemplified by the proliferation of probiotic supplements. 'But no one has truly medicalised the unequivocal science that has built over the last decade on this forgotten organ, and how we can treat and manage it,' Reid says. Microba has commercialised two clinical tests, to assess and manage gastro-intestinal (GI) patients. 'We have been at the forefront of clinical microbiome diagnostics for the last seven years,' the CEO says. Microba spawns from the germ of a good idea Reid says Brisbane-based Microba 'sits at the intersection of the integrity of the gastro-intestinal tract, the structure and function of the microbiome, and the communication between the brain and the gut.' The company's flagship Metaxplore tests assess a range of markers to assess the gastro-intestinal tract. 'It then distills that into a clear report with findings and - most importantly - what the clinicians can in terms of diet, dietary supplementation, targeted medications and specific lifestyle changes,' Reid says. Microba was formed in 2017 based on intellectual property acquired from the University of Queensland. The patents built on the work of the co-founders Prof Philip Hugenholtz and Prof Gene Tyson at institutions including University of California Berkeley, Massachusetts Institute of Technology and the Joint Genome Institute. Reid was an associate director of Uniquest Pty Ltd and held roles with plant genetics leader Dupont Pioneer, and biotechnology innovator Novozymes. The company's deputy chair, Prof Ian Frazer, co-invented the Gardasil and Cervarix cervical cancer vaccines. The company launched its first non-diagnostic product, Microba Insight, in Australia in July 2018. This delivered the world's 'largest clinically applicable, proprietary microbiome dataset'. Microba listed on April 5, 2022, at a subscription price of 45 cents, with the initial public offer raising $30 million. The company launched its core clinical testing products Metaxplore and Metapanel, in February 2023 and March 2024 respectively (see below). In November 2023, Microba expanded into the UK with the strategic acquisition of private UK microbiome testing business Invivo Clinica, for an upfront GBP5 million ($A10.4 million). In late 2022, ASX-listed pathology giant Sonic Healthcare invested $17.8 million to acquire a 19.99% holding in Microba. In October 2024, the company sold its non-core research services business and this year has been discontinuing legacy products. In late April, Microba entered a partnership with the Colonoscopy Clinic, one of Australia's largest private gastro-intestinal operations, seeing about 10,000 patients a year. The guts of Microba The Microba business is based on a proprietary database of one million microbial genomes, covering thousands of species. Rather than 'dying in a sea of opportunity', the company has focused on gastro-intestinal disease. 'Ninety-five per cent of those organisms live in the gut and will act there first, before they have their systemic impact through the body,' Reid says. Metapanel is the 'first line' test to determine whether the patient has a pathogen that can be treated simply with antibiotics. While other screening panels are available, they only detect 15 to 25 pathogens, whereas Metaxplore can deal with more than 100. 'Metapanel rules out the simplest root causes first - 'bad guy? yes or no' - while Metaxplore deals with the complexity of everything else that could be wrong with that patient's gastro-intestinal and microbiome health,' Reid says. As with a standard pathology assay, clinicians refer both tests to patients. The patient sends back a stool test sample with the supplied kit. The clinicians interpret the reports - which are designed to be 'simple and actionable' - just before the patient visits. Metapanel study In May, Microba released the 'compelling' results of a study called Metapanel, which analysed 889 test results from patients' long-term gastro-intestinal symptoms. The results showed that 20% of patients (178 of them) tested positive for a pathogen that can cause gastro-intestinal infection. Of the pathogens detected, 78% were missed by routine pathology tests. Furthermore, 58% of tests showed abnormal microbiome results, supporting referral to a Metaxplore test for further investigation. All the patients treated showed 'complete symptom resolution' in an independent study. All results are reviewed by an expert pathologist that recommends treatments, including antibiotic selection. Metaxplore study A week later, Microba announced the results of a 'landmark' gastro-intestinal study, covering more than 4600 patients undergoing Metaxplore testing. Of these, 71.4% had 'actionable results' with 42% testing positive for abnormal microbiome markers linked to gastro-intestinal health. About 10% tested positive for gastro-intestinal markers, such as inflammation, pancreatic insufficiency or stool blood. Almost 20% tested positive for multiple markers (microbiome and gastro-intestinal). The crux is that 65% of patients reported health improvements after following their doctor's advice (based on the Metaxplore findings). Eyes on the US prize Currently Metaxplore is sold in Australia and in the UK, while Metapanel is available locally via Sonic. Reid says Microba has a 'well considered plan' for US rollout. 'The US market is a big pie, so we have a plan to take it one slice and one bite at a time,' Reid says. 'Our strategy is to start in one state and one city, with a small team. In effect we will replicate what we did in the UK, accessing influential clinicians and then opening up to more.' The company estimates a total addressable market of $25 billion covering 82 million patients, across the US, the UK, Germany, Italy, Spain, France and Australia. 'Bugs as drugs' For the last five years, Microba has developed a pipeline of novel therapeutics across three programs. Think of them as prescription probiotics, or 'bugs as drugs'. The company has completed a phase I study for ulcerative colitis; and has pre-clinical programs for immune-oncology and auto-immune conditions. Ulcerative colitis is one of the two major forms of irritable bowel disease, which results in inflammation and ulcers (sores) in the digestive tract. It is a debilitating, chronic condition - and poorly treated. In December 2023, the company reported the phase I study of 32 healthy volunteers, showing Microba's drug candidate MAP-315 was 'well tolerated at both low and high doses'. The company plans an investigational new drug application to the US Food and Drug Administration, to enable a phase II trial. Finances and performance In late June, Microba completed a $14.5 million capital raise, with a $12.5 million two-tranche placement and a fully-underwritten share plan for $2 million, both at nine cents a share, a 22% discount. The shares come with options, exercisable at 14 cents within two years. Sonic Healthcare ponied up $4.1 million and has indicated a further potential commitment of $4.1 million more. Microba posted record core test sales in the March quarter. Locally, the company sold 3,225 Metaxplore tests, more than triple the previous period, taking the annualised run rate to 12,900 tests, also up 200%. In the UK, the company sold 246 Metaxplore tests, with turnover doubling between February and March. Meanwhile, the company achieved 212 local Metapanel sales, up 1,827%. Cash receipts totalled $4.23 million for the quarter, up 5.2% on a year previously. Revenue fell 14% to $3.4 million, reflecting an 84% decline in (legacy) research work. Microba guided to revenue of $15.25 million to $16.25 million for the year to June 30, 2025, and in late June narrowed this to $15.4 million to $16 million. Management expects Australia and the UK to be break-even this year. Post raising, the company has a proforma cash position of $26.29 million. Over the last 12 months, Microba shares have wavered between 32 cents (January 28, 2025) and eight cents (July 2 this year). The Microba register includes Thorney Investments (Tiga Trading) and Perennial Value Management. Who's payin' … just sayin' Normally patients are like your columnist with the first shout: short arms and long pockets. Unlike most medical diagnostic plays, Microba is not exactly hanging out for US reimbursement because patients are willing to stump up because they're in so much long-term pain. 'We don't need it to have a ginormous business,' Reid says. 'There is a hungry, cash-pay market that's bigger than people understand.' That said, the company wouldn't exactly snub US reimbursement. Microba's price modelling settled on $470 for Metaxplore in Australia. In the UK, the price is £399 ($A830) per test. In the US, the price looks like coming in at anywhere between US$450 and US$800 ($688 to $1224). Currently sold just in Australia via Sonic, a Metapanel test sells for $345. The obvious gambit is to bundle the tests in a 'two-for-one' special, involving only one medical consultation. This is something for the future. Dr Boreham's diagnosis: Reid says after years of work and investment, Microba has transitioned from being 'R&D heavy' to 'capital light, partnering and revenue-focused'. 'We have a significant revenue base that is growing quickly,' he says. 'We aren't waiting for the promise of approvals or reimbursement; we have real product in the market getting value and delivering clinical results.' While Microba estimates a US$25 billion a year market for 82 million tests, it hones the 'addressable' market within three years to 18 million tests and an 'obtainable' market of two million assays. Do the sums and the revenue rewards are still humungous. In the US alone, 37 million patients present each year with a range of symptoms and half of them are not resolved. 'We only need to unlock a fraction of a percent to meet our business objectives,' Reid says. In the meantime, Microba shares have more than halved over the last year and a crica $50 million valuation does not do justice to these achievements. But in the pantheon of ASX biotechs, this is not a unique story and patient investors should be rewarded in the fullness of time. At a glance: ASX Code: MAP Share price: 9.4 cents Market cap: $48 million Chief executive officer: Dr Luke Reid
Daily Mail
3 days ago
- Health
- Daily Mail
Over 2 MILLION pounds lost and counting! For less than $1 a day, shed pounds with the cravings killer users say is a 'weight loss game-changer'
Daily Mail journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission - learn more There are millions of quick fixes for weight loss. Some actually work, others — much to the collective dismay of countless people — simply don't. When the fad diets and intense workouts feel unsustainable, it may be time to rethink your approach. With fewer rules to follow and more energy to gain, Bioma gives you an entirely new way to think about shedding pounds. Bioma Support your weight loss goals from the inside out with this gut-focused formula packed with clinically studied probiotic strains. Each serving includes B. longum, B. lactis, and B. breve. These ingredients are known to boost natural GLP-1 production, reduce cortisol levels, and promote fat metabolism. All the while, it minimizes inflammation. Plus, it nourishes your gut to help your body maintain a healthy microbiome. Using it is super simple, too. Two a day is all you need! You couldn't ask for more of a weight support supplement. From $25.99 Shop It's a great deal right now, which breaks down to less than $1 a day. That translates to a very steady weight loss journey that is far more likely to both attain and sustain. The idea here is that weight issues begin in your gut. Like so many other health concerns, research reveals that the answer may actually lie deep within your microbiome. Bioma zeroes in specifically on the types of bacteria that reside in the gut. Studies show that certain probiotic strains can influence everything from appetite and metabolism to belly fat and even your stress levels. The brand is committed to essentially overhauling your gut — and giving you a new lease on life by making it easier to finally lose the unwanted pounds that may have felt like a struggle to get rid of before. With more than 338,000 users and over 2 million pounds collectively lost in 2024 alone, this gut-first supplement has transformed the way that people think about weight loss. Instead of focusing on willpower alone, Bioma works by optimizing your gut's microbiome. This is the internal support system that makes digestion, energy, and fat metabolism possible. Each serving delivers three powerhouse probiotic strains, including B. longum, B. lactis, and B. breve. They're specifically chosen because of their impact on weight. The 3-pack bundle is an excellent deal, but you can also snap up a single bottle if you'd like to give it a test drive to see how well it works for you Notably, they've been shown to naturally increase GLP-1 (the same hormone targeted by weight loss injections), reduce stress-induced cortisol, and support the breakdown of stubborn abdominal fat. Bioma also includes xylooligosaccharides (XOS), a unique prebiotic that essentially acts as fuel for these helpful bacteria. Another key ingredient is tributyrin, a postbiotic that helps create the ideal gut environment so your body can reap the complete benefits. 'Thanks to Bioma, I've lost 10 pounds in a month. It's been a game-changer for my weight loss journey,' raves one shopper. 'Highly recommend it!' 'I've lost 15 pounds in just two months with Bioma,' shares another. 'It's easy to use, and I feel healthier and more energetic every day.' 'Bioma solved my bloating and other gut problems in just a few weeks,' says a third. 'I feel lighter, healthier, and so much more comfortable every day.' If you have tried everything else to no avail, it may be time to give your body the shift it's needed for a long time. Give Bioma a try and experience the difference!
